A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the
percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with
levodopa.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.